Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Harvard Medical School
Boston, Massachusetts
The records below are financial disclosure and conflict of interest records obtained by ProPublica from the National Institutes of Health and dozens of large public universities across the country. The NIH only has records for researchers who seek or receive its funding.
Total Disclosures: 98
| Name | Type | Company | Disclosed Value | Year Filed |
|---|---|---|---|---|
| Levi Garraway | Conflict of Interest | Foundation Medicine, Inc. | >$600,000 | 2015 |
| Bernardo Sabatini | Conflict of Interest | OptogeniX | >$600,000 | 2015 |
| David Sinclair | Conflict of Interest | OvaScience | >$600,000 | 2014 |
| Joseph Newhouse | Conflict of Interest | Aetna, Inc. | >$600,000 | 2016 |
| David Sinclair | Conflict of Interest | Cohbar, Inc. | >$600,000 | 2017 |
| David Sinclair | Conflict of Interest | Life Biosciences | $250,000 - $299,999 | 2018 |
| Caroline Shamu | Conflict of Interest | Merrimack Pharmaceuticals, Inc. | $200,000 - $249,999 | 2014 |
| Caroline Shamu | Conflict of Interest | Merrimack Pharmaceuticals, Inc. | $200,000 - $249,999 | 2014 |
| Peter Sorger | Conflict of Interest | Merrimack Pharmaceuticals, Inc. | $200,000 - $249,999 | 2014 |
| Peter Sorger | Conflict of Interest | Merrimack Pharmaceuticals, Inc. | $200,000 - $249,999 | 2014 |
| Cigall Kadoch | Conflict of Interest | Foghorn Therapeutics | $200,000 - $249,999 | 2019 |
| Joseph Newhouse | Conflict of Interest | Aetna, Inc. | $150,000 - $199,999 | 2014 |
| Peng Yin | Conflict of Interest | Ultivue | $100,000 - $149,999 | 2018 |
| Peng Yin | Conflict of Interest | Ultivue, Inc. | $100,000 - $149,999 | 2015 |
| Joseph Newhouse | Conflict of Interest | Aetna, Inc. | $100,000 - $149,999 | 2014 |
| Peng Yin | Conflict of Interest | Ultivue, Inc. | $100,000 - $149,999 | 2016 |
| Loren Walensky | Conflict of Interest | Aileron Therapeutics | $100,000 - $149,999 | 2014 |
| Levi Garraway | Conflict of Interest | Foundation Medicine, Inc. | $80,000 - $99,999 | 2015 |
| Joseph Newhouse | Conflict of Interest | Aetna, Inc. | $60,000 - $79,999 | 2016 |
| David Sinclair | Conflict of Interest | Senolytic Therapeutics | $40,000 - $59,999 | 2019 |
| Daniel Finley | Conflict of Interest | Proteostasis Therapeutics, Inc. | $40,000 - $59,999 | 2017 |
| David Sinclair | Conflict of Interest | GlaxoSmithKline | $40,000 - $59,999 | 2016 |
| Donald Ingber | Conflict of Interest | Emulate, Inc. | $40,000 - $59,999 | 2015 |
| David Sinclair | Conflict of Interest | Ovscience | $40,000 - $59,999 | 2017 |
| David Sinclair | Conflict of Interest | Ovscience | $40,000 - $59,999 | 2017 |
| Stephen Liberles | Conflict of Interest | Kallyope Inc. | $20,000 - $39,999 | 2017 |
| Daniel Finley | Conflict of Interest | Proteostasis Therapeutics, Inc. | $20,000 - $39,999 | 2017 |
| Daniel Finley | Conflict of Interest | Proteostasis Therapeutics, Inc. | $20,000 - $39,999 | 2017 |
| George Church | Conflict of Interest | Editas Medicine | $20,000 - $39,999 | 2016 |
| Peter Sorger | Conflict of Interest | Merrimack Pharmaceuticals, Inc. | $10,000 - $19,999 | 2014 |
| Peter Sorger | Conflict of Interest | Merrimack Pharmaceuticals, Inc. | $10,000 - $19,999 | 2014 |
| Caroline Shamu | Conflict of Interest | Merrimack Pharmaceuticals, Inc. | $10,000 - $19,999 | 2014 |
| Peter Sorger | Conflict of Interest | RareCyte | $10,000 - $19,999 | 2018 |
| Peter Sorger | Conflict of Interest | RareCyte, Inc. | $10,000 - $19,999 | 2018 |
| Bernardo Sabatini | Conflict of Interest | OptogeniX | $10,000 - $19,999 | 2015 |
| David Sinclair | Conflict of Interest | OvaScience | $10,000 - $19,999 | 2014 |
| Stephen Lory | Conflict of Interest | x-Biotix | $10,000 - $19,999 | 2018 |
| Caroline Shamu | Conflict of Interest | Merrimack Pharmaceuticals, Inc. | $10,000 - $19,999 | 2014 |
| Bernardo Sabatini | Conflict of Interest | OptogeniX | $5,000 - $9,999 | 2015 |
| David R. Andes | Conflict of Interest | Astellas | $5,000 - $9,999 | 2015 |
| David R. Andes | Conflict of Interest | Cubist | $5,000 - $9,999 | 2015 |
| David Sinclair | Conflict of Interest | OvaScience | $5,000 - $9,999 | 2014 |
| David Sinclair | Conflict of Interest | GlaxoSmithKline | $5,000 - $9,999 | 2016 |
| Peter Sorger | Conflict of Interest | Glencoe Software | $0 - $4,999 | 2018 |
| Peter Sorger | Conflict of Interest | Merrimack Pharmaceuticals, Inc. | $0 - $4,999 | 2014 |
| Caroline Shamu | Conflict of Interest | Merrimack Pharmaceuticals, Inc. | $0 - $4,999 | 2014 |
| Chao-Ting Wu | Conflict of Interest | GC Therapeutics | $0 - $4,999 | 2019 |
| Peter Sorger | Conflict of Interest | Merrimack Pharmaceuticals, Inc. | $0 - $4,999 | 2014 |
| Jeffrey Harper | Conflict of Interest | Rheostat Therapeutics Inc. | $0 - $4,999 | 2019 |
| Caroline Shamu | Conflict of Interest | Merrimack Pharmaceuticals, Inc. | $0 - $4,999 | 2014 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.